Back to results
US 2023/0414773 A1Published application
Elp fusion proteins for controlled and sustained release
OwnerJamie JOWETT, David James BALLANCEinventors
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutical formulations for sustained release, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The disclosure provides improved pharma-cokinetics for peptide and small molecule drugs.
Claims26
1-28. (canceled)
A sustained release pharmaceutical formulation comprising:
- a therapeutic agent, the therapeutic agent comprising an active agent and an ELP amino acid sequence comprising [VPGXG]144 or [XPGVG]144, where each X is selected from V, G, and A, and wherein the ELP exhibits a transition temperature between 26° C. and 37° C., and one or more pharmaceutically acceptable excipients.
(canceled)
(canceled)
46-47. (canceled)
(canceled)
54-57. (canceled)
Dependencies are inferred from the claim text.